Polyrizon Ltd PLRZ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $11.58
- Day Range
- $11.10–12.60
- 52-Week Range
- $2.88–18.20
- Bid/Ask
- $10.45 / $12.50
- Shares Outstanding
- 2.08M
- Market Cap
- $23.19M
- Volume/Avg
- 27,355 / 42,739
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. The company's technology platforms are Capture & Contain and Trap & Target.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 1
Valuation
|
Metric
|
PLRZ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.90 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PLRZ
|
|---|---|
Quick Ratio | 28.14 |
Current Ratio | 29.03 |
Interest Coverage | — |
Quick Ratio
PLRZ
Profitability
|
Metric
|
PLRZ
|
|---|---|
Return on Assets (Normalized) | −46.64% |
Return on Equity (Normalized) | −47.76% |
Return on Invested Capital (Normalized) | −50.25% |
Return on Assets
PLRZ
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Rpyjjmjk | Vpchpgt | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xgpxgrlp | Pxyyf | $64B | |||
| argenx SE ADR
ARGX
| Hxlqdpvxb | Sbhh | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mxrwpmtfb | Sbnld | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Sgdxwkqb | Tzflbs | $24B | |||
| BioNTech SE ADR
BNTX
| Pqgsdty | Fmpn | $23B | |||
| Incyte Corp
INCY
| Hzghnzm | Gntjx | $22B | |||
| Moderna Inc
MRNA
| Fprzfhr | Lvx | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Ycvrmtbk | Vfgz | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Cfsdxytq | Gwhw | $13B |
United States